Equities

SIGY

US82674U2050

Market Closed - OTC Markets Other stock markets 12:27:32 2024-05-15 EDT			5-day change	1st Jan Change
5.25 ^USD	+5.00%		+5.00%	+10.99%

02-20	Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	CI

Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 13, 2022 at 12:35 pm

Sigyn Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 0.678046 million compared to USD 0.461682 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.

Latest news about SIGN THERPAR

Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	12-12	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application	23-05-17	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Sigyn Therapeutics, Inc. Announces Appointment of Annette Marleau as Chief Scientific Officer	23-04-11	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Sigyn Therapeutics, Inc. Announces Cancer-Related Patent Submission	22-10-06	CI
Sigyn Therapeutics, Inc. Announces Board Changes, Effective October 10, 2022	22-10-04	CI
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients	22-09-14	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Sigyn Therapeutics, Inc. has filed an IPO in the amount of $9.2 million.	22-06-22	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board	22-04-26	CI
Sigyn Therapeutics, Inc. Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board	22-03-31	CI
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Sigyn Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-20	CI
Sigyn Therapeutics, Inc. Appoints H. David Humes, MD to Its Scientific Advisory Board	22-03-15	CI
Sigyn Therapeutics, Inc. Appoints Alexander S. Yevzlin to its Scientific Advisory Board	22-03-09	CI
Sigyn Therapeutics, Inc. Appoints Jeremy Ferrell as Chief Financial Officer, Effective March 9, 2022	22-03-02	CI
Sigyn Therapeutics Announces Completion of Animal Studies	22-02-23	CI
Sigyn Therapeutics, Inc. Reports the Successful Completion of A Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis	21-12-01	CI

Chart SIGN THERPAR

Duration

Period

More charts

Company Profile

Sigyn Therapeutics, Inc. is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.

Sector

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar